SABCS 2021 | PROCURE: Genomic signatures and adjuvant chemotherapy for breast cancer in Europe
Giuseppe Curigliano • 9 Dec 2021
Giuseppe Curigliano, MD, PhD, University of Milan and European Institute of Oncology, Milan, Italy, discusses the PROCURE project, a survey across European investigators about use of genomic signatures to make decisions about adjuvant chemotherapy use in early breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.
Disclosures
Consultation fees from Pfizer, Roche, Astra Zeneca, BMS, Daichii Sankyo, Seagen, Gilead, Novartis, Lilly; Ellipsis, Merck
